Brief: Poxel Announces New Strategic Direction

Poxel SA

12/07/2021 07:06

July 12 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL ANNOUNCES NEW STRATEGIC DIRECTION WITH INCREASING
FOCUS ON
RARE METABOLIC DISEASES FOLLOWING RECENT ACHIEVEMENTS
    * TO ACCELERATE AND EXPAND RARE METABOLIC DISEASE PROGRAMS
LEVERAGING EXISTING PLATFORMS AND PROVEN CAPABILITIES
    * TO ADVANCE ITS DEUTERATED THIAZOLIDINEDIONES (DTZD) AND
DIRECT
ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE (AMPK)
ACTIVATOR PLATFORMS IN RARE METABOLIC DISEASES WITH INITIATION
OF PXL065 AND PXL770 PHASE 2A CLINICAL PROOF-OF-CONCEPT (POC)
STUDIES IN X-LINKED ADRENOLEUKODYSTROPHY (ALD) IN EARLY 2022
    * DATA EXPECTED IN Q4 2022
    * CONTINUED COMMITMENT TO NON-ALCOHOLIC STEATOHEPATITIS
(NASH)
THROUGH PXL065 DESTINY PHASE 2 TRIAL WITH RESULTS EXPECTED IN Q3
2022
    * REASSESSMENT OF PXL770 FUTURE DEVELOPMENT IN NASH PENDING
RESULTS FROM PXL065 PHASE 2 TRIAL AND BOTH PHASE 2A POC STUDIES
IN ALD

Source text for Eikon:  ID:nBw7v9mL1a 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))